Eli Lilly's experimental obesity therapy bimagrumab drew mixed reactions from Wall Street after the company recently ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...

Truist ging in op zorgen over verhoogde leverenzymen die naar voren kwamen na de orforglipron-presentatie. Hoewel sommige KOL's voorzichtig waren met deze signalen gezien het potentiële langdurige ...

Some doctors are concerned that patients taking weight loss drugs like Wegovy may be losing too much lean mass. A combination ...

Het dividend zal op 10 september 2025 worden uitgekeerd aan aandeelhouders die op 15 augustus 2025 geregistreerd staan, aldus een persbericht van het bedrijf.

Eli Lilly's bimagrumab led to weight loss that was due almost entirely to fat reduction when combined with semaglutide, ...

Eli Lilly & Co.'s experimental weight loss pill helped patients shed pounds without serious side effects in a clinical trial, ...

Fueled by a sustained boom in sales of its diabetes and obesity products, Eli Lilly will become the world’s top-seller of prescription drugs by 2030 and will hold the top rung by a wide margin. | ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...

Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on ...